There are 30+ gene therapies approved across medicine. ABBV-RGX-314 is targeting wet AMD and is in global pivotal trials with positive preliminary trials to date, thanks @JasonHsuMD #RSLisbon2024 @Wills_Eye @MidAtl_Retina @REGENXBIO @abbvie
Phase 2 subretinal gene therapy of ABBV-RGX-314 in previously treated wet AMD showed good tolerance with few cases of inflammation responsive to steroid drops + stable vision and edema with over 70% injection free over 6 mos. @allenho #RSLisbon2024 @RetinaSociety @Wills_EyeView quoted post on X